SCHEMBL2908491

SCHEMBL2908491

Cc1cccc(-c2nc(NCc3ccc(Cl)cc3)c3ccccc3n2)n1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE5A O76074 5/20 0.68
APP P05067 2/20 0.59
USP1 O94782 2/20 0.58
WDR48 Q8TAF3 2/20 0.58
MEN1 O00255 6/20 0.58
KMT2A Q03164 6/20 0.58
NPC1 O15118 1/20 0.58
TGFBR1 P36897 5/20 0.55
MAPK14 Q16539 1/20 0.55
GBA1 P04062 1/20 0.54
ATM Q13315 1/20 0.54
LMNA P02545 3/20 0.53
MAPT P10636 2/20 0.53
EGFR P00533 1/20 0.52
ALDH1A1 P00352 2/20 0.52
KDM4E B2RXH2 1/20 0.52
HPGD P15428 1/20 0.52
USP2 O75604 1/20 0.50
CYP1A2 P05177 1/20 0.50
CYP3A4 P08684 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2909029 0.88 PDE5A (0.71) PDE5AAPPUSP1WDR48MEN1
SCHEMBL2906534 0.82 TGFBR1 (0.76) PDE5ATGFBR1MAPK14LMNAMAPT
SCHEMBL2591972 0.81 PDE5A (1.00) PDE5AAPPUSP1WDR48MEN1
SCHEMBL12176179 0.80 APP (0.71) PDE5AAPPUSP1WDR48KMT2A
SCHEMBL2583256 0.79 PDE5A (0.90) PDE5AAPPUSP1WDR48MEN1
SCHEMBL12176337 0.77 PDE5A (0.85) PDE5AAPPUSP1WDR48MEN1
SCHEMBL3106597 0.77 APP (0.85) PDE5AAPPUSP1WDR48MEN1
SCHEMBL16280938 0.77 RAD52 (0.79) PDE5AAPPKMT2ALMNAMAPT
SCHEMBL16280681 0.77 RAD52 (0.69) PDE5AAPPKMT2ALMNAMAPT
SCHEMBL4866252 0.76 PDE5A (0.78) PDE5AAPPUSP1WDR48MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1966184-B1 PYRIDINYL-QUINAZOLINE DERIVATIVES AND THEIR MEDICAL USE NEUROSEARCH AS (DK) 2010-08-25 EP claimed
US-20090306102-A1 2-PYRIDIN-2-YL-QUINAZOLINE DERIVATIVES AS POTASSIUM CHANNEL MODULATING AGENTS FOR THE TREATMENT OF RESPIRATORY DISEASES NEUROSEARCH A/S (DK) 2009-12-10 US claimed
EP-1966184-B1 PYRIDINYL-QUINAZOLINE DERIVATIVES AND THEIR MEDICAL USE NEUROSEARCH AS (DK) 2010-08-25 EP disclosed
US-20090306102-A1 2-PYRIDIN-2-YL-QUINAZOLINE DERIVATIVES AS POTASSIUM CHANNEL MODULATING AGENTS FOR THE TREATMENT OF RESPIRATORY DISEASES NEUROSEARCH A/S (DK) 2009-12-10 US disclosed
EP-1966184-A2 PYRIDINYL-QUINAZOLINE DERIVATIVES AND THEIR MEDICAL USE NeuroSearch A/S (DK) 2008-09-10 EP disclosed
WO-2007071632-A2 2-PYRIDIN-2-YL-QUINAZOLINE DERIVATIVES AS POTASSIUM CHANNEL MODULATING AGENTS FOR THE TREATMENT OF RESPIRATORY DISEASES NEUROSEARCH A/S (DK) 2007-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306102-A1 2-PYRIDIN-2-YL-QUINAZOLINE DERIVATIVES AS POTASSIUM CHANNEL MODULATING AGENTS FOR THE TREATMENT OF RESPIRATORY DISEASES KCNJ2, KCNQ1, KCNK2 PDE5A 697/4885APP 2376/4885USP1 4186/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.